These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 2656447)

  • 1. [Significance of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine for the etiology and therapy of idiopathic Parkinson disease].
    Lange KW
    Fortschr Neurol Psychiatr; 1989 Apr; 57(4):142-8. PubMed ID: 2656447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
    Jenner P; Marsden CD
    J Neural Transm Suppl; 1986; 20():11-39. PubMed ID: 3091760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MPTP: a pharmacological tool to study parkinsonism.
    Kulkarni SK; Mehta AK; Aley KO; Shukla VK
    Methods Find Exp Clin Pharmacol; 1986 Aug; 8(8):485-9. PubMed ID: 3489146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The clinical syndrome of striatal dopamine deficiency. Parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
    Burns RS; LeWitt PA; Ebert MH; Pakkenberg H; Kopin IJ
    N Engl J Med; 1985 May; 312(22):1418-21. PubMed ID: 2581135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
    Nishi K; Kondo T; Narabayashi H
    No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys.
    Forno LS; Langston JW; DeLanney LE; Irwin I; Ricaurte GA
    Ann Neurol; 1986 Oct; 20(4):449-55. PubMed ID: 3024555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D; Gross C; Lebrun-Grandié P; Bioulac B
    C R Seances Soc Biol Fil; 1985; 179(1):85-97. PubMed ID: 3161601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The MPTP model of Parkinson's disease.
    Smeyne RJ; Jackson-Lewis V
    Brain Res Mol Brain Res; 2005 Mar; 134(1):57-66. PubMed ID: 15790530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for neuromelanin involvement in MPTP-induced neurotoxicity.
    D'Amato RJ; Alexander GM; Schwartzman RJ; Kitt CA; Price DL; Snyder SH
    Nature; 1987 May 28-Jun 3; 327(6120):324-6. PubMed ID: 2884568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Parkinsonism induced by MPTP as an experimental model of Parkinson disease: similarities and differences].
    Luquin MR; Obeso JA; Herrero MT; Laguna J; Martínez-Lage JM
    Neurologia; 1991 Oct; 6(8):287-94. PubMed ID: 1790005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of the central noradrenergic system in MPTP-induced monkey parkinsonism.
    Miyoshi R; Kito S; Ishida H; Katayama S
    Res Commun Chem Pathol Pharmacol; 1988 Oct; 62(1):93-102. PubMed ID: 2849789
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A simple quantitative bradykinesia test in MPTP-treated mice.
    Ogawa N; Hirose Y; Ohara S; Ono T; Watanabe Y
    Res Commun Chem Pathol Pharmacol; 1985 Dec; 50(3):435-41. PubMed ID: 3878557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On the mechanisms underlying 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity: the effect of perinigral infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, its metabolite and their analogs in the rat.
    Harik SI; Schmidley JW; Iacofano LA; Blue P; Arora PK; Sayre LM
    J Pharmacol Exp Ther; 1987 May; 241(2):669-76. PubMed ID: 2437293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experimental model of Parkinson disease: mechanisms and anatomo- pathological characteristics of MPTP neurotoxicity].
    Herrero MT; Luquín MR; Obeso JA
    Arch Neurobiol (Madr); 1992; 55(4):175-82. PubMed ID: 1417423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Saccade responses to dopamine in human MPTP-induced parkinsonism.
    Hotson JR; Langston EB; Langston JW
    Ann Neurol; 1986 Oct; 20(4):456-63. PubMed ID: 3491578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiparkinsonian actions of ifenprodil in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Fox SH; Henry B; Hill MP; Peggs D; McGuire S; Maneuf Y; Hille C; Brotchie JM; Crossman AR
    Exp Neurol; 2000 Sep; 165(1):136-42. PubMed ID: 10964492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parkinson's disease in 1984: an update.
    Lang AE; Blair RD
    Can Med Assoc J; 1984 Nov; 131(9):1031-7. PubMed ID: 6388779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic activation of azaheterocyclics induced dopaminergic toxicity: possible candidate neurotoxins underlying idiopathic Parkinson's disease].
    Matsubara K
    Nihon Hoigaku Zasshi; 1998 Oct; 52(5):301-5. PubMed ID: 10077975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Unilateral MPTP-induced parkinsonism in monkeys. A quantitative autoradiographic study of dopamine D1 and D2 receptors and re-uptake sites.
    Przedborski S; Jackson-Lewis V; Popilskis S; Kostic V; Levivier M; Fahn S; Cadet JL
    Neurochirurgie; 1991; 37(6):377-82. PubMed ID: 1780015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.